Posts by Nabeel Bardeesy, PhD
-
Combined EGFR/FGFR Inhibitor Therapy Proposed for FGFR2-Positive Intrahepatic Cholangiocarcinoma
By analyzing patient-derived models of FGFR2 fusion–positive intrahepatic cholangiocarcinoma, scientists at the Mass General Cancer Center determined feedback activation of EGFR-dependent signaling limits the efficacy of FGFR inhibitors and combined EGFR/FGFR inhibition may be a therapeutic solution.
-
Novel Strategy Proposed To Enhanced Treatment of Cholangiocarcinoma With IDH1 Mutations
Meng-Ju Wu, PhD, Nabeel Bardeesy, PhD, Robert Manguso PhD, and colleagues found in a mouse model of cholangiocarcinoma that immune function and the interferon-gamma/TET2 axis are essential for response to mutant IDH1 inhibitors, and they suggest a novel strategy for boosting the efficacy of these inhibitors.
-
Loss of REDD1 "Reprograms" Lipid Metabolism to Drive Progression of RAS-Mutant Tumors
Leif W. Ellisen, MD, PhD and Nabeel Bardeesy, PhD, of the Cancer Center, and colleagues have demonstrated that loss of the stress response gene REDD1 drives progression and poor clinical outcomes in RAS-mutant tumors—and is a potentially therapeutically actionable feature of these cancers.
Biography
Nabeel Bardeesy, PhD, is an assistant geneticist in the Center for Cancer Research at the Massachusetts General Hospital Cancer Center and an associate professor of medicine at Harvard Medical School.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
